Bupropion


Aminoketone NDRI / nicotinic antagonist

An aminoketone norepinephrine and dopamine reuptake inhibitor FDA-approved for depression (Wellbutrin) and smoking cessation (Zyban).

Abstract

Bupropion (Wellbutrin, Zyban; CAS 34911-55-2; molecular formula C13H18ClNO; molecular weight 239.74) is a unicyclic aminoketone developed by Burroughs Wellcome and approved by the FDA in 1985 for major depressive disorder, with subsequent approval for smoking cessation (1997) and seasonal affective disorder. Mechanism is selective inhibition of norepinephrine and dopamine reuptake (NDRI) plus non-competitive nicotinic acetylcholine receptor antagonism. The active metabolite hydroxybupropion contributes substantially to the antidepressant activity. Pharmacokinetics: parent half-life ~14 hours; CYP2B6 metabolism. Lowers seizure threshold; contraindicated in seizure disorders and bulimia.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph